Skip to main content

Table 1 Characteristics of patients with and without AEs

From: Costs associated with adverse events from remission induction for children with Acute Lymphoblastic Leukemia (ALL)

Variables

Patients 

with AEs (n = 46)

Patients 

without AEs (n = 7)

p value

Age (years)

7.00 (4.44)

6.00 (2.64)

0.802a

Weight (kg)

27.04 (18.17)

22.40 (11.46)

0.813a

Height (cm)

115.66 (26.68)

111.00 (16.27)

0.727a

Female, n (%)

25 (54.35)

3 (42.86)

0.694a

High risk ALL, n (%)

27 (58.70)

3 (42.86)

0.451a

Standard risk ALL, n (%)

19 (41.30)

4 (57.14)

0.451a

Completed RICP, n (%)

43 (93.48)

7 (100)

0.487a

ALL remission, n (%)

45 (97.83)

7 (100)

0.694a

Deaths, n (%)

4 (8.70)

0 (0)

0.417a

Time to get ALL remission (days)

15.55 (5.97)

15.28 (3.35)

0.747a

First hospital length of stay (days)

9.33 (13.65)

1.86 (4.91)

0.006a

Second hospital length of stay (days)

6.62 (9.74)

0.14 (0.37)

0.101a

Third hospital length of stay (days)

1.35 (6.25)

0 (0)

0.491a

Amount of AEs by patient

6.46 (6.06)

0 (0)

< (0) 01a

  1. The values shown are mean and standard deviations except for percentages
  2. AEs Adverse events
  3. aWilcoxon rank sum test